Effect of temperature on 3,4-Methylenedioxypyrovalerone (MDPV)-induced metabolome disruption in primary mouse hepatic

Ana Margarida Araújo1, Maria de Lourdes Bastos1, Félix Carvalho1

  • 1UCIBIO, REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal.

Toxicology
|May 30, 2020
PubMed

Insights

3,4-Methylenedioxypyrovalerone (MDPV) causes liver damage, especially under high temperatures. This study used metabolomics to reveal how MDPV disrupts cellular metabolism in mouse liver cells, highlighting increased risks during hyperthermia.

Area of Science:

  • Toxicology
  • Metabolomics
  • Hepatology

Background:

  • 3,4-Methylenedioxypyrovalerone (MDPV) is a widely used cathinone derivative linked to intoxications and fatalities.
  • Hyperthermia is implicated in MDPV-related deaths, but its role in MDPV-induced hepatotoxicity is poorly understood.

Purpose of the Study:

  • To investigate the metabolic effects of MDPV on primary mouse hepatocytes (PMH) under normothermic and hyperthermic conditions.
  • To elucidate the mechanisms of MDPV hepatotoxicity, particularly under elevated temperatures.

Main Methods:

  • Utilized a gas chromatography-mass spectrometry (GC-MS) based untargeted metabolomic approach.
  • Exposed PMH to varying concentrations of MDPV (LC01, LC10, LC30) at 37°C and 40.5°C for 24 hours.
  • Evaluated intracellular metabolome and extracellular volatilome alterations.

Main Results:

  • Multivariate analysis revealed distinct metabolic profiles for MDPV-exposed cells versus controls, even at subtoxic concentrations.
  • Normothermia showed dysregulation in ascorbate metabolism, TCA cycle, and pyruvate metabolism.
  • Hyperthermia (40.5°C) exacerbated these changes and affected additional pathways including aspartate/glutamate metabolism and aminoacyl-tRNA biosynthesis.

Conclusions:

  • MDPV exposure significantly alters cellular metabolism in primary mouse hepatocytes.
  • Hyperthermia intensifies MDPV-induced metabolic disruption, suggesting heightened hepatotoxicity risks under feverish conditions.
  • Findings offer new insights into MDPV hepatotoxicity mechanisms, emphasizing the critical role of temperature.

Related Concept Videos

Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
455
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs01:21

Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs

A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
643
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
143
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.4K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
117